Evidence map›Paper›PMID 28893116›Full record

ArticleMolecular imaging

Imaging Hepatocellular Carcinoma With

Carina Mari Aparici, Spencer C Behr, Youngho Seo, R Kate Kelley, Carlos Corvera, Kenneth T Gao, Rahul Aggarwal, Michael J Evans

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular imaging. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2022
    Article
  2. The Evaluation ofMolecular imaging and biology · 2021
    Article
  3. Quantitative and Qualitative Improvement of Low-Count [Molecular imaging and biology · 2020
    Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Carina Mari Aparici1 Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, CA, USA.
Spencer C Behr1 Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, CA, USA.
Youngho Seo1 Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, CA, USA.
R Kate Kelley2 Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, USA.
Carlos Corvera3 Department of Surgery, University of California, San Francisco, San Francisco, CA, USA.
Kenneth T Gao1 Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, CA, USA.
Rahul Aggarwal2 Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, USA.
Michael J Evans1 Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, CA, USA.
University of California, San Francisco · USUCSF Helen Diller Family Comprehensive Cancer Center · US

Funding

Translational InformaticsP30CA082103 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Jennifer Leigh Clarke · 1999 to 2026
$209.7M
UCSF Liver Core CenterP30DK026743 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Holger Willenbring · 1986 to 2026
$30.7M
Annotating Oncogene Status in Prostate Cancer with Zr-89-transferrin PETR01CA176671 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI EVANS, MICHAEL JOHN, LEWIS, JASON S. · 2013 to 2017
$3.1M
Pretherapy 124I-MIBG Dosimetry for Planning 131I-MIBG Neuroblastoma TherapyR01CA154561 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI SEO, YOUNGHO · 2011 to 2016
$1.9M
Noninvasive measurement of oncogenic signaling pathways with 89Zr-transferrinR00CA172695 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI EVANS, MICHAEL JOHN · 2014 to 2016
$728k
NCI NIH HHS P30 CA082103NCI NIH HHS R00 CA172695NCI NIH HHS R01 CA154561NCI NIH HHS R01 CA176671NIDDK NIH HHS P30 DK026743
6 · The paper itself

Abstract

While cross-sectional imaging with computed tomography (CT) and magnetic resonance imaging is the primary method for diagnosing hepatocellular carcinoma (HCC), they provide little biological insight into this molecularly heterogeneous disease. Nuclear imaging tools that can detect molecular subsets of tumors could greatly improve diagnosis and management of HCC. To this end, we conducted a patient study to determine whether HCC can be resolved using

Indexed as

Positron-Emission TomographyAdultCarcinoma, HepatocellularCitratesGalliumHumansLiverLiver NeoplasmsMaleTransferrinCitratesGalliumgallium citrateTransferrinhepatocellular carcinomamolecular imagingtransferrintransferrin receptor

Identifiers

PMID28893116
PMCPMC5598799
OpenAlexW2756465600

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.